RXRX vs. IBB
RXRX (Recursion Pharmaceuticals, Inc.) is a stock, while IBB (iShares Nasdaq Biotechnology ETF) is Health & Biotech Equities fund tracking the NASDAQ Biotechnology Index. Over the past 5 years, RXRX returned -33.59%/yr vs 2.57%/yr for IBB. A 0.58 correlation means they provide meaningful diversification when combined.
Performance
RXRX vs. IBB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RXRX achieves a -7.09% return, which is significantly lower than IBB's 1.65% return.
RXRX
- 1D
- 9.51%
- 1M
- 12.76%
- YTD
- -7.09%
- 6M
- -22.76%
- 1Y
- -22.61%
- 3Y*
- -23.33%
- 5Y*
- -33.59%
- 10Y*
- —
IBB
- 1D
- 2.35%
- 1M
- 0.64%
- YTD
- 1.65%
- 6M
- -0.21%
- 1Y
- 37.34%
- 3Y*
- 10.11%
- 5Y*
- 2.57%
- 10Y*
- 6.32%
RXRX vs. IBB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RXRX Recursion Pharmaceuticals, Inc. | -7.09% | -39.50% | -31.44% | 27.89% | -54.99% | -45.27% |
IBB iShares Nasdaq Biotechnology ETF | 1.65% | 27.98% | -2.41% | 3.76% | -13.69% | -0.30% |
Correlation
The correlation between RXRX and IBB is 0.53, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.53 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.57 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.59 |
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021 | 0.58 |
The correlation between RXRX and IBB has been stable across timeframes, ranging from 0.53 to 0.58 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RXRX vs. IBB — Risk / Return Rank
RXRX
IBB
RXRX vs. IBB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RXRX | IBB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.19 | ||
| Sortino ratioReturn per unit of downside risk | -2.66 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.32 | -0.32 |
| Calmar ratioReturn relative to maximum drawdown | -0.39 | 3.89 | -4.28 |
| Martin ratioReturn relative to average drawdown | -0.64 | 12.34 | -12.98 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| RXRX | IBB | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.31 | 1.88 | -2.19 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.36 | 0.12 | -0.48 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.27 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.36 | 0.26 | -0.62 |
Drawdowns
RXRX vs. IBB - Drawdown Comparison
The maximum RXRX drawdown since its inception was -93.13%, which is greater than IBB's maximum drawdown of -62.85%. Use the drawdown chart below to compare losses from any high point for RXRX and IBB.
Loading charts...
Drawdown Indicators
| RXRX | IBB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.13% | -62.85% | -30.28% |
Max Drawdown (1Y)Largest decline over 1 year | -58.17% | -9.63% | -48.54% |
Max Drawdown (3Y)Largest decline over 3 years | -82.09% | -24.85% | -57.24% |
Max Drawdown (5Y)Largest decline over 5 years | -93.13% | -39.82% | -53.31% |
Max Drawdown (10Y)Largest decline over 10 years | — | -39.82% | — |
Current DrawdownCurrent decline from peak | -90.81% | -3.43% | -87.38% |
Average DrawdownAverage peak-to-trough decline | -75.36% | -21.18% | -54.18% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.28% | 3.04% | +32.24% |
Volatility
RXRX vs. IBB - Volatility Comparison
Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 20.35% compared to iShares Nasdaq Biotechnology ETF (IBB) at 7.26%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than IBB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RXRX | IBB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 20.35% | 7.26% | +13.09% |
Volatility (6M)Calculated over the trailing 6-month period | 45.51% | 15.55% | +29.96% |
Volatility (1Y)Calculated over the trailing 1-year period | 74.04% | 19.99% | +54.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 93.56% | 22.01% | +71.55% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 93.66% | 23.23% | +70.43% |
Dividends
RXRX vs. IBB - Dividend Comparison
RXRX has not paid dividends to shareholders, while IBB's dividend yield for the trailing twelve months is around 0.23%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.23% | 0.23% | 0.29% | 0.26% | 0.31% | 0.21% | 0.21% | 0.33% | 0.20% | 0.30% | 0.19% | 0.03% |
RXRX Recursion Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
RXRX and IBB have a correlation of 0.53, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RXRX has higher volatility (20.35%) compared to IBB (7.26%). In terms of maximum drawdown, RXRX dropped -93.13% vs IBB's -62.85%.
IBB currently has the higher Sharpe Ratio (1.88 vs -0.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RXRX and IBB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer